• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Doximity (DOCS) Cheap As Its Clinical AI Tool Tops Safety Benchmark?

    Simply Wall St·07/16/2026 17:34:40
    语音播报

    Doximity (DOCS) is back in focus after reporting that its HIPAA compliant clinical AI tool, Doximity Ask, ranked first for safety in the independent NOHARM benchmark run by Stanford and Harvard physicians.

    See our latest analysis for Doximity.

    Doximity’s share price has shown a short burst of strength, with a 1 month share price return of 7.64% and a 7 day share price return of 2.63%. However, this follows a much weaker period where the year to date share price return is down 48.58% and the 1 year total shareholder return has fallen 64.34%, suggesting recent enthusiasm around clinical AI and governance updates is still set against a longer period of pressure.

    If Doximity’s AI progress has caught your eye, this could be a moment to see what other healthcare AI stocks are on the move using the 40 healthcare AI stocks

    So after Doximity’s sharp share price slide and this recent bounce on clinical AI news, is it more sensible to step in at today’s levels or wait for a clearer margin of safety before committing fresh capital?

    Most Popular Narrative: 33.9% Undervalued

    Based on the most followed Doximity narrative, a fair value of $33.70 sits well above the recent close at $22.26, which frames the recent AI driven excitement in a very different light.

    What I like about Doximity is that there really is a very high viewership / user base of active practicing Physicians in the US and that is not invaluable and definitely could be monetized perhaps more efficiently. I also think that Doximity offers a lot of interesting tools for Physicians a lot of which you’re free and really marketed towards I think Physicians who are more in private practice. It’s a little bit unclear how much value that provides given that most Physicians and practitioners these days are employed and not a private practice.

    Read the complete narrative.

    The fair value in this narrative leans heavily on how far Doximity can push revenue per clinician, keep margins healthy, and justify a premium earnings multiple. It raises the question of which specific growth and profitability assumptions are doing the heavy lifting in that $33.70 figure and how sensitive it could be to even small changes in those inputs.

    Result: Fair Value of $33.70 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, Doximity’s 3 year and 5 year total shareholder returns have both declined sharply, and tighter competition in clinical AI tools could pressure assumptions about future monetization.

    Find out about the key risks to this Doximity narrative.

    Next Steps

    If the mixed tone around Doximity has you unsure, this is a good moment to act quickly and review the full picture yourself by checking the 2 key rewards

    Looking for more investment ideas beyond Doximity?

    If Doximity has sharpened your focus on quality and risk, do not stop here. Broaden your watchlist with fresh ideas from the Simply Wall St screener.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.